The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
The company plans to add 1700 beds by FY27 through the organic route
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Express Scripts to add Zepbound to National Preferred Formulary
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
The disease is caused by a mutation in the gene encoding HMG CoA reductase, inhibiting the enzyme’s activity.
Subscribe To Our Newsletter & Stay Updated
